EssilorLuxottica - ADR
ESLOY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2025
July 28, 2025 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
10.8% downsideOvervalued by 10.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $97.06 Billion |
|---|---|
| Enterprise Value | $110.56 Billion |
| Dividend Yield | $2.35 (2.19%) |
| Earnings per Share | $2.42 |
| Beta | 0.53 |
| Outstanding Shares | 926,453,000 |
Return
| Return on Equity | 12.01% |
|---|---|
| Return on Assets | 7.31% |
| Return on Invested Capital | 13.19% |
Valuation & Multiples
| P/E Ratio | 36.56 |
|---|---|
| PEG | -498.67 |
| Price to Sales | 1.81 |
| Price to Book Ratio | 2.54 |
| Enterprise Value to Revenue | 2.01 |
| Enterprise Value to EBIT | 16.2 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 0.00% |
|---|---|
| Total Invested | $5.32M▼ 31.06% |
| Investors Holding | 10▼ 7.00% |
ESG Score
No data
About EssilorLuxottica
Relevant Senate Committees
This committee's analysis and 'scoring' of tax legislation directly influences corporate tax rates, capital investment credits, and other tax policies that significantly impact EssilorLuxottica's financial performance and strategic decisions.
This committee's control over taxation (corporate tax policy), trade (tariffs on components or finished goods), and entitlement spending (Medicare/Medicaid coverage for eyewear) directly impacts EssilorLuxottica's profitability, supply chain, and market access.
This committee directly allocates federal spending. Its decisions on funding for the VA, DOD, or NIH (for research into vision-related issues) could directly impact demand for EssilorLuxottica's products and research opportunities.
The committee's jurisdiction over health policy, including medical device regulation (FDA), and labor laws directly impacts manufacturing costs, product approvals, and the overall healthcare market for ophthalmic goods.
This committee's oversight of antitrust laws and intellectual property is highly relevant to EssilorLuxottica, a large entity in a potentially consolidated industry. Antitrust reviews of future acquisitions or IP protections are critical.
As a manufacturer of ophthalmic goods, EssilorLuxottica likely supplies products to government healthcare providers, including the VA. Funding and policy decisions from this committee directly impact demand and contracts.